<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04281355</url>
  </required_header>
  <id_info>
    <org_study_id>EUBREAST-2 INDAX</org_study_id>
    <nct_id>NCT04281355</nct_id>
  </id_info>
  <brief_title>Individualized Locoregional Treatment of Initially Biopsy-proven Node-positive Breast Cancer After Primary Systemic Therapy</brief_title>
  <acronym>INDAX</acronym>
  <official_title>Individualized Locoregional Treatment of Initially Biopsy-proven Node-positive Breast Cancer After Primary Systemic Therapy: The EUBREAST-2 INDAX Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karolinska Institutet</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In clinically node-positive (cN+) breast cancer, preoperative systemic therapy (PST) is&#xD;
      common. With increasing rates of complete tumour eradication, there is a need for&#xD;
      de-escalation of locoregional treatment in the interest of decreased morbidity.&#xD;
&#xD;
      In order to individually adapt postoperative therapies, axillary staging is crucial. Axillary&#xD;
      lymph node dissection (ALND) comes at a high risk of arm morbidity. There is extreme&#xD;
      divergence in the use of less extensive staging methods, i.e. targeted lymph node biopsy&#xD;
      (TLNB), sentinel node biopsy (SNB) or both (TAD), and in the use of subsequent locoregional&#xD;
      treatment, since prospective data are largely lacking.&#xD;
&#xD;
      The main purpose of the European INDAX trial is to implement de-escalated staging and&#xD;
      evaluate which regional treatment, individually adapted to the response after PST, is&#xD;
      oncologically safe but least harmful.&#xD;
&#xD;
      Population: cN+ breast cancer patients receiving PST, recruited 2021-2025. Staging by TLNB,&#xD;
      TAD or SNB.&#xD;
&#xD;
      Intervention: Negative staging (ypN0, Randomisation A, N=1433): no regional treatment.&#xD;
      Positive staging (ypN+, Randomisation B, N=1513): no ALND but regional radiotherapy (rRT).&#xD;
&#xD;
      Control: Randomisation A: rRT only. Randomisation B: ALND plus rRT.&#xD;
&#xD;
      Outcome: Invasive disease-free survival (non-inferiority), arm morbidity and quality of life.&#xD;
&#xD;
      Drug tests in whole-tumour organoid cultures, algorithm-based digital image analysis and gene&#xD;
      expression analysis are performed to improve response prediction, facilitate tailoring of PST&#xD;
      and increase eradication rates.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    lack of funding&#xD;
  </why_stopped>
  <start_date type="Anticipated">January 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2029</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>iDFS</measure>
    <time_frame>5 years</time_frame>
    <description>Invasive disease-free survival</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Randomisation A - Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In pathologically node-negative patients on axillary staging (TAD, TLNB, SLNB) after primary systemic treatment, no regional radiotherapy is given and no axillary lymph node dissection are performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Randomisation B - Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In pathologically node-positive patients on axillary staging (TAD, TLNB, SLNB) after primary systemic treatment, full axillary and regional radiotherapy is given but no axillary lymph node dissection performed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Omission of axillary lymph node dissection</intervention_name>
    <description>Axillary lymph node dissection will be replaced by axillary radiotherapy in Randomisation B</description>
    <arm_group_label>Randomisation A - Intervention</arm_group_label>
    <arm_group_label>Randomisation B - Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Omission of regional irradiation</intervention_name>
    <description>Regional irradiation will be omitted in the interventional arm of Randomisation A.</description>
    <arm_group_label>Randomisation A - Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with primary invasive breast cancer cT1-cT3&#xD;
&#xD;
          -  cN1 status prior to PST&#xD;
&#xD;
          -  Cytological or histological proof of axillary metastasis before PST&#xD;
&#xD;
          -  Full tumour biology available before initiation of PST&#xD;
&#xD;
          -  Oral and written consent&#xD;
&#xD;
          -  Age â‰¥ 18 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Biopsy-confirmed regional nodal metastases outside of the ipsilateral axilla&#xD;
&#xD;
          -  Distant metastases at diagnosis&#xD;
&#xD;
          -  Inflammatory breast cancer&#xD;
&#xD;
          -  Previous axillary surgery&#xD;
&#xD;
          -  Previous radiotherapy to ipsilateral breast, chest or axilla&#xD;
&#xD;
          -  History of prior invasive breast cancer&#xD;
&#xD;
          -  Ongoing pregnancy or breast-feeding&#xD;
&#xD;
          -  Bilateral invasive breast cancer&#xD;
&#xD;
          -  Medical contraindication for radiotherapy or inability to receive recommended&#xD;
             radiotherapy&#xD;
&#xD;
          -  Medical contraindication for adjuvant endocrine treatment, if indicated&#xD;
&#xD;
          -  Inability to absorb or understand the meaning of the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 20, 2020</study_first_submitted>
  <study_first_submitted_qc>February 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 24, 2020</study_first_posted>
  <last_update_submitted>February 23, 2021</last_update_submitted>
  <last_update_submitted_qc>February 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska Institutet</investigator_affiliation>
    <investigator_full_name>Jana de Boniface</investigator_full_name>
    <investigator_title>Sponsor-Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

